Human Immunodeficiency Virus clinical trials

Explore recruiting human immunodeficiency virus clinical trials.

Recruiting human immunodeficiency virus studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Human Immunodeficiency Virus trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Safety and Impact of Dasatinib on Viral Persistence and Inflammation in People with HIV under Antiretroviral Treatment

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3 Open-label Clinical Study of Doravirine/Islatravir (DOR/ISL [100 mg/0.25 mg]) Once Daily for the Treatment of HIV-1 Infection in Participants Who Previously Received DOR/ISL (100 mg/0.75 mg) QD in a Phase 3 Clinical Study

France, Germany, Spain, Italy, Finland, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

Immune response to the recombinant Zoster Vaccine in people living with HIV over 50 years of age compared to non-HIV age- and gender-matched controls - Shingr'HIV

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3b, multicenter, single-arm, open-label study evaluating the efficacy, safety, and tolerability of switching to DTG/3TC single tablet regimen administered once daily from a bictegravir/emtricitabine/tenofovir alafenamide single tablet regimen in people living with HIV of at least 50 years of age who are virologically suppressed

Belgium, Italy, Portugal, Austria, Spain, Germany +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of MK-8527 Oral Once-Monthly as HIV-1 Preexposure Prophylaxis

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

IAVI C110 HIV Vaccine Trial

Netherlands

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Human Immunodeficiency Virus trials by city

Human Immunodeficiency Virus in Toronto Human Immunodeficiency Virus in Vancouver Human Immunodeficiency Virus in Montreal Human Immunodeficiency Virus in Calgary Human Immunodeficiency Virus in Edmonton Human Immunodeficiency Virus in Ottawa Human Immunodeficiency Virus in Winnipeg Human Immunodeficiency Virus in Quebec City Human Immunodeficiency Virus in Hamilton Human Immunodeficiency Virus in Kitchener Human Immunodeficiency Virus in London Human Immunodeficiency Virus in Halifax Human Immunodeficiency Virus in New York Human Immunodeficiency Virus in Los Angeles Human Immunodeficiency Virus in Chicago Human Immunodeficiency Virus in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease